Skip to search formSkip to main contentSkip to account menu

6 ML RADIUM CHLORIDE RA-223 30 MCI/ML Injection [Xofigo]

Known as: Xofigo 1100 kBq/ML in 6 ML Injection, Xofigo (radium Ra-223 dichloride) 6600 kBq per 6 ML Injection, RADIUM RA-223 DICHLORIDE 30 uCi in 1 mL INTRAVENOUS INJECTION [Xofigo] 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Background and Objective: Radium-223 dichloride (Xofigo®) is a calcium mimetic agent approved for the treatment of castration… 
2018
2018
Over the last decade several radiopharmaceutical agents have shown a real benefit for patients who had limited therapeutic… 
Review
2017
Review
2017
Prostate cancer is the most common malignant disease in men. Several therapeutic agents have been approved during the last 10… 
2017
2017
The integrity of the genome of eukaryotic cells is secured by complex signaling pathways, known as DNA damage response (DDR… 
2016
2016
Radium-223 dichloride (Xofigo®; 223Ra) is an alpha-emitting radiopharmaceutical FDA-approved for the treatment of bone metastases… 
Review
2015
Review
2015
Objectives: Prostate cancer (PC) is the most common cancer in Western countries. Recent advances in the treatment of metastatic… 
2015
2015
Prostate cancer (PC) is the most common neoplasm in men in Western countries, and approximately 10 – 20 % of patients with PC… 
Review
2014
Review
2014
Radium-223 dichloride (Xofigo®; formerly Alpharadin™) [hereafter referred to as radium-223] is a first-in-class alpha particle… 
2014
2014
In patients with advanced castration-resistant prostate cancer (CRPC), symptomatic bone metastases are frequently present. Xofigo…